PLYMOUTH MEETING, Pa., Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of INOVIO's management team will also be conducting in-person one-on-one meetings with investors.
H.C. Wainwright 27th Annual Global Investment Conference
Presentation available: Beginning Friday, September 5, 2025, 7:00AM ET
Format: Pre-recorded webcast
Link: https://journey.ct.events/view/c0cc4d12-f619-4d58-878f-4ee305e4f2c2
The webcast will be available for 90 days at the link above or on the INOVIO Investor Relations Events page: https://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$2.15 |
| Daily Change: | 0.03 1.42 |
| Daily Volume: | 2,634,700 |
| Market Cap: | US$114.250M |
November 10, 2025 November 10, 2025 November 03, 2025 October 21, 2025 August 26, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load